- ASCO •
- 3 June, 2024 •
- •
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL
Michal Kwiatek , Carmelo Carlo-Stella , Andrzej Urban, Andrew Niewiarowski, Luqiang Wang, Mehdi Hamadani